Sildenafil and assessment of pulmonary arterial reactivity in heart failure.
Pulmonary hypertension is a daunting accompaniment of advanced heart failure. Efforts to safely and consistently lower pulmonary vascular resistance are necessary but fraught with challenges. In this report the authors explore the novel use of sildenafil, an inhibitor of phosphodiesterase-5, in tackling pulmonary hypertension in heart failure. The salutary effects of this agent deserve further study.
Alaeddini
Jamshid
J
Cardiomyopathy and Heart Transplantation Center, Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
Uber
Patricia
P
Park
Myung H
MH
Scott
Robert L
RL
Mehra
Mandeep R
MR
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000627:therapeutic use*; D006333:Heart Failure / Q000150:complications; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases